Louis Matis
Plus aucun poste en cours
Profil
Louis A.
Matis served as President & CEO of Gilead Connecticut, Inc. from 2000 to 2006, and as CEO of Immune Tolerance Institute, Inc. from 2007 to 2010.
He also held positions as Chief Scientific Officer & SVP at Alexion Pharmaceuticals, Inc. and as Principal at National Cancer Institute.
Matis was Chief Development Officer & SVP at Pieris Pharmaceuticals, Inc. from 2015 to 2020.
He received his undergraduate degree from Amherst College and his doctorate from Perelman School of Medicine.
Anciens postes connus de Louis Matis
| Sociétés | Poste | Fin |
|---|---|---|
| PIERIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 10/01/2020 |
Immune Tolerance Institute, Inc.
 Immune Tolerance Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of The David H. Murdock Research Institute, Immune Tolerance Institute, Inc. provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms. The company is based in Menlo Park, CA. Immune Tolerance Institute was acquired by The David H. Murdock Research Institute on June 09, 2011. | Directeur Général | 01/01/2010 |
Gilead Connecticut, Inc.
 Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | Directeur Général | 01/01/2006 |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
| ALEXION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Louis Matis
| Amherst College | Undergraduate Degree |
| Perelman School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Gilead Connecticut, Inc.
Gilead Connecticut, Inc. Pharmaceuticals: MajorHealth Technology Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
Immune Tolerance Institute, Inc.
Immune Tolerance Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of The David H. Murdock Research Institute, Immune Tolerance Institute, Inc. provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms. The company is based in Menlo Park, CA. Immune Tolerance Institute was acquired by The David H. Murdock Research Institute on June 09, 2011. | Commercial Services |
